Doxorubicin market players and analysis by application, by distribution channel- forecast till 2030. The global doxorubicin market is projected to have a steady growth rate at a whopping 6.2% CAGR over the forecast period (2022-2030). Doxorubicin, also known as anthracycline, is a type of chemotherapy drug that works by inhibiting the enzyme topo isomerase to slow or stop the growth of cancer cells. This medication is used either by itself or in combination with other medications to treat a variety of malignancies, including those of the ovary, stomach, bladder, lung, breast, non-Hodgkin and Hodgkin lymphomas, neuroblastoma, and some types of leukaemia. The course of treatment depends on the type of cancer being treated, the patient's response to the medication, and any other medications the patient is taking at the time. Both lyophilized powder form and injectable solution are available for doxorubicin. Typically, central venous catheters (CVC) or peripherally implanted central line catheters are used to give it intravenously (PICC).
There are abundant factors that is propelling the growth of the doxorubicin market. These factors as per the MRFR (Market Research Future) report include increasing prevalence of various forms of cancer, boost in geriatric population, growing awareness of cancer treatment and inclusion of the drug in different applications such as AIDS-related Kaposi Sarcoma and neuroblastoma, growing cancer treatment awareness programs, large presence of ablation and surgical centers and technological advancements.
On the other hand, strict regulatory authorities, various cost-control measures implemented by different governments, and a number of doxorubicin-related adverse effects are elements that are anticipated to impede the expansion of the doxorubicin market. Doxorubicin has a number of common adverse effects, including mouth inflammation, rash, vomiting, bone marrow suppression, hair loss, allergic responses, namely anaphylaxis, tissue damage due to the location of the injection, heart damage, leukaemia treatment side effects, and radiation recall. The market expansion for doxorubicin is being hampered by all of these side effects and more.
Key Players
Leading players profiled in the doxorubicin market include GLENMARK PHARMACEUTICALS LTD, Teva Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Sandoz, Novartis AG, Accord Healthcare, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Pfizer, Inc, and various others.
Market Segmentation
MRFR report offers a broad analysis of the doxorubicin market is segmental on the basis of application and distribution channel.
Based on application, the doxorubicin market is segmented into leukemia, ovarian cancer, stomach cancer, prostate cancer, bone sarcoma, breast cancer, gastric cancer, liver cancer and others. Of these, prostate and breast cancer will have the largest share in the market over the forecast period.
Based on distribution channel, the doxorubicin market is segmented into retail pharmacy, hospital pharmacy and others. Of these, hospital pharmacy is projected to lead the market over the forecast period.
Regional Analysis
By region, the doxorubicin market covers growth opportunities and latest trends across Americas, the Middle East and Africa, Europe and Asia Pacific. Of these, the Americas will remain the vital contributor in the market over the forecast period. Factors attributed for the market growth in this region include favorable regulatory authorities and reimbursement, awareness about cancer treatment, increase in cancer cases and presence of leading manufacturers.
The doxorubicin market in Europe will account for the second major share owing to rising healthcare expenditure and increasing pool of cancer patients. In the APAC region, the doxorubicin market is projected to grow at the fastest pace over the forecast period. This is on account of growing geriatric population especially in China and India, growing number of manufacturers looking for opportunities in developing countries, government investment and initiatives for the healthcare sector development and increasing cancer treatment awareness programs. On the other hand, the doxorubicin market in the Middle East and Africa is prognosticated to have minimal share over the forecast period.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact Us:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com
